Quince Therapeutics Announces FDA Has Lifted Partial Clinical Hold Lifted On IND For EryDel's Lead Phase 3 Asset EryDex
Portfolio Pulse from Benzinga Newsdesk
Quince Therapeutics announced that the FDA has lifted the partial clinical hold on the Investigational New Drug (IND) application for EryDel's lead Phase 3 asset EryDex.
September 28, 2023 | 8:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quince Therapeutics' IND application for EryDex has been approved by the FDA, allowing the company to proceed with their Phase 3 trials.
The FDA lifting the partial clinical hold on the IND application for EryDex is a positive development for Quince Therapeutics. This allows the company to proceed with their Phase 3 trials, which could potentially lead to the approval and commercialization of EryDex. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100